Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Onconova Therapeutics (ONTX)

Add to Watchlists
Create an Alert
5.91 -0.25  -4.06% NASDAQ Apr 23, 10:40AM BATS Real time Currency in USD
View Full Chart
ONTX Price Chart
View All Performance Charts

ONTX Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Onconova Therapeutics is up N/A over the last year vs S&P 500 Total Return up 22.75%, Endocyte up 38.00%, and ARCA biopharma down 40.34%.

Get Quote for

Portfolio Strategies Featuring ONTX

Did Onconova Therapeutics make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

ONTX Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: Pennsylvania
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Onconova Therapeutics Inc is engaged in the discovery and development of small molecule product candidates for the treatment of cancer. The Company has three clinical-stage product candidates and six preclinical programs.

Recent Quotes

Symbol Price Chg Chg % Market Cap
ONTX 5.91 -0.25 -4.06% 127.88M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.